<DOC>
	<DOCNO>NCT01381874</DOCNO>
	<brief_summary>The purpose study assess safety efficacy oral abiraterone acetate plus oral prednisone oral abiraterone acetate plus oral prednisone plus oral exemestane , compare oral exemestane alone , postmenopausal woman estrogen receptor-positive ( ER+ ) metastatic ( spread ) breast cancer relapse treatment letrozole anastrozole .</brief_summary>
	<brief_title>A Study Abiraterone Acetate Plus Prednisone With Without Exemestane Postmenopausal Women With Estrogen Receptor-Positive ( ER+ ) Metastatic Breast Cancer Progressing After Letrozole Anastrozole Therapy</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( participant know identity assign study drug ) study divide three phase , screen , treatment , follow-up . During screening , potential patient assess study eligibility provide sign informed consent . The treatment phase comprise series 28-day cycle continuous study treatment breast cancer progression , end-of-treatment visit complete follow-up phase begin . The duration participation study individual patient may approximately 7 year , include follow-up evaluation . Patients evaluate safety effectiveness study treatment . During treatment phase , patient take follow study drug mouth daily : abiraterone acetate , 1 g/day , four 250-mg tablet , empty stomach , patient must eat least 1 hour abiraterone acetate ; prednisone ( prednisolone prednisone available ) , 5 mg/day ; exemestane , 25 mg/day , single tablet . The treatment phase consist series 28-day cycle continuous study treatment breast cancer progression . At planned interim analysis , Data Review Committee recommend randomization abiraterone acetate alone group stop study continued otherwise .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Female patient must postmenopausal ER+ , Human epidermal growth factor receptor 2 ( Her2 ) negative metastatic breast cancer Disease must sensitive anastrozole letrozole therapy prior disease progression No two prior line therapy metastatic setting , one chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status score &lt; =1 Patients disease confine bone may include , patient purely sclerotic lesion may participate study Prior treatment exemestane , ketoconazole , aminoglutethimide , CYP17 inhibitor . Prior treatment ketoconazole &lt; = 7 day permit topical formulation ketoconazole permit Potential patient must take anastrozole , letrozole , fulvestrant , chemotherapy least 2 week ( bevacizumab least 3 week ) randomization Anticancer immunotherapy investigational agent within 4 week randomization , anticancer radiotherapy ( except palliative ) anticancer endocrine therapy within 2 week randomization Serious uncontrolled nonmalignant disease , include active uncontrolled infection Clinical biochemical evidence hyperaldosteronism hypopituitarism Any condition , opinion investigator , would compromise wellbeing patient could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Metastatic</keyword>
</DOC>